$CUE News

Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate

Watching Cue Biopharma; Fugazi Research Issues Report On Co. Titled "$CUE: Reverse Splits, PIPE Dilution, and the Illusion of Recovery"

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma Announces Private Placement For Gross Proceeds Of ~$30M, Selling Pre‑Funded Warrants For Up To 2.7M Shares And Accompanying $11 Warrants For 1.36M Shares

Cue Biopharma Enters Into Exclusive License Agreement With Ascendant Health To Develop, Manufacture And Commercialize Ascendant-221, Phase 2 Clinical Stage Anti-IgE Monoclonal Antibody For Treatment Of Allergic Diseases

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

What's Behind The Drop In Cue Biopharma Stock Today?

Cue Biopharma shares are trading lower after the company announced a 1-for-30 reverse stock split.

Cue Biopharma Announces 1-For-30 Reverse Stock Split Effective After Market Close On April 23

Cue Biopharma shares are trading higher. The company announced it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, at IMMUNOLOGY2026.

Cue Biopharma shares are trading higher after the company announced it received a $7.5 million milestone payment from Boehringer Ingelheim.

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases - Slideshow

Cue Biopharma To Receive $7.5M Milestone Payment Under Collaboration And License Agreement With Boehringer Ingelheim Following Approval Of Its First Lead Optimization Compound; Payment Expected May 2026

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma President, CEO Usman Azam Steps Down, Effective March 26; Lucinda Warren Named Interim President, CEO

Cue Biopharma Files Prospectus For Up To $300M Offering Of Debt, Stock, Warrants, And Units

Cue Biopharma shares are trading higher after the company reported better-than-expected Q4 EPS results and a year-over-year increase in Q4 sales results.

Cue Biopharma Q4 EPS $0.01 Beats $(0.10) Estimate, Sales $21.942M Up From $1.576M Prior Year